AstraZeneca has announced an agreement with the Trump administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.
CEO of AstraZeneca, Pascal Soriot, joined the President at the While House to confirm that the company will voluntarily meet all requests set out in the President’s 31st July letter.
The company agrees to a range of measures which will enable American patients to access medicines at prices that are equal to those available in other wealthy countries.
As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices.
AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.
AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling it to fully onshore its medicines manufacturing.
This will mean all of its medicines sold in America are made in America.
To achieve this, AstraZeneca recently announced $50bn investment in US medicines manufacturing and R&D during the next five years to help deliver $80bn in total revenue by 2030.
Fifty per cent of this is expected to be generated in the US.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices."
"This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines."
"It is now essential that other wealthy countries step up their contribution to fund innovation.”
AstraZeneca’s commitment to the US and American patients is further reflected in the company’s largest single investment in a manufacturing facility to date, which broke ground yesterday in Virginia.
This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline.
Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week.
Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland, early next year.
Its second major R&D centre in Cambridge, Massachusetts, will also open in late 2026.